Other Publication Details
Mandatory Fields
Editorial
Walsh, EM,Shalaby, A,O'Loughlin, M,Keane, N,Webber, MJ,Kerin, MJ,Keane, MM,Glynn, SA,Callagy, GM
2019
February
Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy
Published
1
Optional Fields
Triple negative Breast cancer Survival Pathological complete response Neoadjuvant Carboplatin SURGICAL ADJUVANT BREAST PATHOLOGICAL COMPLETE RESPONSE PHASE-II PREOPERATIVE CHEMOTHERAPY 1ST-LINE CHEMOTHERAPY CLINICAL ONCOLOGY/COLLEGE DIFFERENTIAL RESPONSE TREATMENT STRATEGIES AMERICAN SOCIETY GENE-EXPRESSION
PurposeThe rate of pathological complete response (pCR) for patients with triple negative breast cancer (TNBC) is increased when carboplatin is added to neo-adjuvant chemotherapy (NACT). However, while phase III trial data showing a survival benefit are awaited, carboplatin is not yet standard-of-care for TNBC. The aim of this study was to examine the rate of pCR and the outcome for those treated with carboplatin and to examine the predictors of response to therapy.MethodsThe retrospective series comprised 333 consecutive patients with TNBC (median follow-up time, 43 months). Adjuvant chemotherapy was given to 51% (n=168) of patients and 29% (n=97) received anthracycline-taxane NACT with carboplatin given to 9% (n=31) of patients.ResultsOverall, 25% (n=78) of patients experienced a breast cancer recurrence and 22% (n=68) died from disease. A pCR breast and pCR breast/axilla was more common in those who received carboplatin (n=18, 58% and n=17, 55%, respectively) compared those who did not (n=23, 36% and n=18, 28%, respectively) (p=0.041 and p=0.011, respectively). By multivariable analysis, carboplatin and high tumor grade were independent predictors of pCR breast/axilla (ORnon-pCR=0.17; 95% CI 0.06-0.54; p=0.002; and ORnon-pCR=0.05, 95% CI 0.01-0.27; p<0.001, respectively). pCR breast/axilla was an independent predictor of DFS (HRnon-pCR=6.23; 95% CI 1.36-28.50; p=0.018), metastasis-free survival (HRnon-pCR=5.08; 95% CI 1.09-23.65; p=0.038) and BCSS (HRnon-pCR=8.52; 95% CI 1.09-66.64; p=0.041).ConclusionCarboplatin therapy and high tumor grade are associated with a significant increase in the rate of pCR, which is an independent predictor of outcome. These data support the use of carboplatin in NACT for TNBC, while results from phase III studies are awaited.
1
13
10.1007/s10549-018-5066-6
Grant Details
Publication Themes